Loading…
← CockpitCompetitor Analysis › ZVRA Zevra Therapeutics, Inc.Open in the cockpit ↗

Zevra Therapeutics, Inc.ZVRACompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum weak 30
Mkt cap
$552M
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$11.9M
20-day average traded
Fwd P/E
11.3×
forward earnings
ROIC−WACC
+72.3 pp
WACC 10.1%
Hurdle
-57 pp
Req g minus delivered
Next earnings
112 days
10 Mar 2027
Close · USD$9.28
1D-1.3%
1W-21.7%
1M-11.4%
3M-21.9%
6M-9.4%
YTD+3.6%
1Y+1.1%
ATR %6.9%
Beta1.01
52w lowhigh38.3% off high

What Zevra Therapeutics does

Employees: 61

Zevra Therapeutics at a glance

Size Zevra Therapeutics (ZVRA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $552M, the 2604th largest of 3,085 United States companies the cockpit tracks. Shares closed at $9.28 on 18 Nov 2026.

Performance Over six months the shares fell 9.4%, against -20.3% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 19 in its peer set.

Growth Revenue grew 75.1% over the last twelve months (peer median +0.7%); the operating margin is 31.5% (peer median 6.4%).

Valuation It trades at 11.3× forward earnings against a peer median of 11.3× (5th most expensive of 10).

Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +52%, so the hurdle is -57 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 72.3 points above its cost of capital (10.1% WACC).

Short interest Short interest is 11.0% of the free float (30 Oct 2026).

Next results Next results expected around 10 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026ZVRA 88Peer median 80
Six months, rebased to 100: Zevra Therapeutics against the median of its 20 peers (local-currency closes).

Zevra Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$148M$106M$23.6M$27.5M$10.2M
Revenue growth—+351%-14%+170%—
Gross profit$140M$85.9M$3.57M$23.5M$8.99M
EBITDA$47.9M-$179,000-$80.6M-$48.6M-$24.0M
Net income$75.0M$77.6M-$106M-$46.0M-$26.8M
Free cash flow$38.3M-$2.43M-$69.7M-$33.8M-$18.8M
Capital expenditure$459,000$835,000$0$296,000$93,000
Total debt$1.23M$63.2M$60.3M$43.8M$14.1M

Quarterly statements and history in the cockpit →

Zevra Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-20%0%4559002688003850ACRS002393MOREPENLAB688356SENORESENTXALMS603222SUPRIYA22562157ZVRA6-month return →1-month return →
Up and to the right = strong over both horizons. Zevra Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%+75%20×40×4559002688003850688356SENORESSUPRIYA36132157ZVRARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zevra Therapeutics is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%4559002688003850002393688356000919SUPRIYAEVONILE3613ZVRAGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Zevra Therapeutics is the large dot.

Zevra Therapeutics competitors and peer comparison

How Zevra Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zevra Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureZVRAPeer medianRank in peer set
1-month return-11.4%-10.8%10th lowest of 20
6-month return-9.4%-20.3%4th highest of 19
Distance from 52-week high-38.3%-42.8%6th highest of 20
Revenue growth (TTM)+75.1%+0.7%highest of 20
Operating margin31.5%6.4%2nd highest of 19
Forward P/E11.3×11.3×5th most expensive of 10
Growth the price implies (Req g, 7 yrs)-4.9%1.0%4th least demanding of 10
Growth delivered (Del g)+51.6%+9.7%highest of 10
Hurdle (Req g minus delivered)-56.5 pp-8.7 ppleast demanding of 10
ROIC minus cost of capital+72.3 pp-3.5 pphighest of 17
EV / EBITDA7.5×18.5×3rd cheapest of 8
Net debt / EBITDA-4.1×0.9×least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Zevra Therapeutics ZVRAUnited States$552M-9%+75%31%11.3×-4.9%+51.6%
Zeria Pharmaceutical 4559.TJapan$552M-12%+12%15%9.6×-12.3%+11.1%
Jinhe Biotechnology 002688.SZChina$550M-19%+7%5%8.9×1.0%+9.7%
Boryung 003850.KSSouth Korea$554M-13%+6%6%11.3×-3.1%+12.6%
Aclaris Therapeutics ACRSUnited States$555M-23%-59%-1,412%n/an/an/a
Tianjin Lisheng Pharmaceutical 002393.SZChina$557M-24%-3%7%9.0×-5.8%+4.1%
Zhong Zhu Healthcare 600568.SSChina$562M-22%-6%-34%n/an/an/a
Morepen Laboratories MOREPENLAB.NSIndia$542M+121%+30%11%n/an/an/a
Jenkem Technology 688356.SSChina$563M-30%+52%11%30.2×36.4%+11.2%
Senores Pharmaceuticals SENORES.NSIndia$538M+3%+40%24%32.2×n/an/a
Entera Bio ENTXUnited States$568M+163%-100%n/an/an/an/a
Alumis ALMSUnited States$569M-80%-67%-5,375%n/an/an/a
Chimin Health Management 603222.SSChina$533M-31%+1%-28%n/an/an/a
Electra Therapeutics ETRAUnited States$530Mn/an/an/an/an/an/a
Jinling Pharmaceutical 000919.SZChina$529M-15%-8%1%n/a2.4%+5.0%
Supriya Lifescience SUPRIYA.NSIndia$529M-15%+23%26%36.2×28.2%+15.8%
Evonile Pharma EVONILE.NSIndia$529Mn/a-5%12%n/a49.3%-1.5%
Beijing Tong Ren Tang Chinese Medicine 3613.HKHong Kong$577M-26%-21%32%10.2×-15.4%+2.8%
Abbisko Cayman 2256.HKHong Kong$578M-39%-83%-520%n/an/an/a
Oneness Biotech 4743.TWOTaiwan$580M-13%+19%-589%n/an/an/a
Lepu Biopharma 2157.HKHong Kong$580M-43%+47%7%53.6×n/an/a

Questions

Which companies are Zevra Therapeutics's closest peers?
The cockpit's peer set: Zeria Pharmaceutical (4559.T), Jinhe Biotechnology (002688.SZ), Boryung (003850.KS), Aclaris Therapeutics (ACRS), Tianjin Lisheng Pharmaceutical (002393.SZ), Zhong Zhu Healthcare (600568.SS), Morepen Laboratories (MOREPENLAB.NS), Jenkem Technology (688356.SS).
Is Zevra Therapeutics expensive compared with its peers?
On forward p/e it trades at 11.3× against a peer median of 11.3×, 5th most expensive of 10 in its peer set. For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +52%, so the hurdle is -57 pp: the price already allows for a slowdown.
How has Zevra Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -9.4% against -20.3% for the median peer; over one year +1.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.